Recent high-profile ‘rock star’ media coverage has put a minimally invasive cardiac procedure in the spotlight.
As a practicing physician and the Chief Medical Officer for Image Guided Therapy (IGT) at Philips, I have observed first-hand the rapid evolution of minimally invasive procedures. Our field has made a real difference to patient care and transformed the experience of clinicians.
So, it’s hardly surprising that public awareness of our amazing non-surgical procedures is now increasing. We are becoming accustomed to seeing headlines on how a minimally invasive procedure is “breaking news” on the world stage. Last year, we learned of the non-surgical procedure performed by interventional radiologists to embolize a kidney tumor in the US’ First Lady. And now another image-guided therapy procedure has become the number one news story in the world, leading many of my non-medical friends and family to contact me to understand what exactly happened.
A minimally invasive procedure hits the headlines
Recent high-profile “rock star” media coverage has piqued public interest in a minimally invasive cardiac procedure, known as transcatheter aortic valve replacement (TAVR) – referred to as transcatheter aortic valve implantation (TAVI) in Europe and Asia – used to treat aortic stenosis (AS), one of the most common heart valve diseases.
AS happens when the heart’s aortic valve narrows, preventing the valve from fully opening. This reduces or blocks blood flow from the heart into the main aorta, and on to the rest of the body. When this happens, the heart must work harder to pump blood around the body. This can lead to symptoms such as lightheadedness, shortness of breath or chest pain. Ultimately, if left untreated, AS can be fatal.
Evolving treatment: from open-heart surgery to minimally invasive
AS has traditionally been treated with open-heart surgery with surgical aortic valve replacement (SAVR), a major operation that involves the surgeon opening the chest to access the heart. The procedure can take up to six hours and typically requires a hospital stay of a week or more, with a prolonged recovery time.
First performed in 2002 in a 57-year-old inoperable patient with AS, with TAVR the interventional physician inserts the replacement heart valve, most commonly through a small access site in the patient’s upper thigh. Using advanced x-ray and ultrasound imaging, which is why we call this “image-guided,” the valve is precisely guided to the heart and deployed at the site of the old failing valve. TAVR can be carried out in as little as 90 minutes and most commonly only requires mild sedation, typically avoiding the need for general anesthesia and intubation.
TAVR had been typically performed in patients who were so elderly or unwell that they faced the risk of not surviving open heart surgery. However, recent findings from two clinical trials showed that TAVR was just as useful in younger, healthier patients and may even be more effective.
TAVR: an option for more patients
Presented at the American College of Cardiology (ACC) Meetings earlier this year, both the PARTNER 3 Trial and the CoreValve Low-Risk Trial were conducted on patients who were deemed low-risk surgical candidates, not the usual profile of a patient undergoing TAVR.
Both trials showed notable benefits of TAVR compared to SAVR, including reduced risks of stroke, death and repeat hospital admissions.
Shorter waiting times
It’s not just the patient who benefits – lengthy hospital stays as seen with open-heart surgery can be dramatically reduced, alleviating pressure on hospital resources. It’s likely that wider use of TAVR will result in a corresponding decrease in waiting times for treatments.
The result? Increased satisfaction all round.
Improving access to care
A growing and aging population means that incidence of heart valve disease is only likely to increase. And what goes hand in hand with this is longer waiting times, already in evidence across the globe. On a recent trip to Thailand I learned that the average waiting time for such a procedure could be one year. So, it’s more important than ever to have efficient solutions that can contribute to reduced costs, shorter hospital stays, and improve efficiency and workflow. I believe that TAVR’s adoption will increase worldwide, in no small part because of the leading innovations from Philips in advanced x-ray interventional suites and navigation tools, which help make TAVR more precise and efficient.
Physicians and patients are optimistic that the FDA is anticipated to approve the procedure for lower-risk patients later this year. That would be particularly encouraging news – one study found that nearly two thirds of patients with severe AS do not receive the appropriate treatment.
I’m thrilled to see “rock-star” publicity bring awareness to image-guided therapy innovations like TAVR, which will help get more people back to living the lives they love and doing the things they enjoy.
Chief Medical Officer, Image Guided Therapy at Philips
Atul Gupta, MD, explores how recent high-profile ‘rock star’ media coverage has piqued public interest in a minimally invasive cardiac procedure known as transcatheter aortic valve replacement (TAVR), used to treat aortic stenosis, one of the most common heart valve diseases.
Prior to joining Philips, Dr. Gupta served on the International Medical Advisory Board of Philips for over 10 years. In April 2016, he shifted to officially joining Philips but still maintains a clinical practice. He is working several days per month performing both interventional and diagnostic radiology in suburban Philadelphia, in both hospital and office based lab settings.
Atul has been repeatedly recognized as top physician for his specialty in the media, serves on several advisory boards, has published and lectured internationally for various interventional procedures.